key: cord-0995365-w48whrwr authors: Yang, Shuai; Tong, Ying; Chen, Lu; Yu, Wenqiang title: Human Identical Sequences, hyaluronan, and hymecromone ─ the new mechanism and management of COVID-19 date: 2022-05-20 journal: Mol Biomed DOI: 10.1186/s43556-022-00077-0 sha: 3d072b889997a44d73b81f9f01fabcbf4efd42ec doc_id: 995365 cord_uid: w48whrwr COVID-19 caused by SARS-CoV-2 has created formidable damage to public health and market economy. Currently, SARS-CoV-2 variants has exacerbated the transmission from person-to-person. Even after a great deal of investigation on COVID-19, SARS-CoV-2 is still rampaging globally, emphasizing the urgent need to reformulate effective prevention and treatment strategies. Here, we review the latest research progress of COVID-19 and provide distinct perspectives on the mechanism and management of COVID-19. Specially, we highlight the significance of Human Identical Sequences (HIS), hyaluronan, and hymecromone (“Three-H”) for the understanding and intervention of COVID-19. Firstly, HIS activate inflammation-related genes to influence COVID-19 progress through NamiRNA-Enhancer network. Accumulation of hyaluronan induced by HIS-mediated HAS2 upregulation is a substantial basis for clinical manifestations of COVID-19, especially in lymphocytopenia and pulmonary ground-glass opacity. Secondly, detection of plasma hyaluronan can be effective for evaluating the progression and severity of COVID-19. Thirdly, spike glycoprotein of SARS-CoV-2 may bind to hyaluronan and further serve as an allergen to stimulate allergic reaction, causing sudden adverse effects after vaccination or the aggravation of COVID-19. Finally, antisense oligonucleotides of HIS or inhibitors of hyaluronan synthesis (hymecromone) or antiallergic agents could be promising therapeutic agents for COVID-19. Collectively, Three-H could hold the key to understand the pathogenic mechanism and create effective therapeutic strategies for COVID-19. The ongoing pandemic of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection has resulted in more than 6.2 million deaths globally according to the WHO Coronavirus Dashboard by April 27, 2022 . Along with the increase in global infections and deaths, the economic burden and health threats caused variants of concern (VOC) by WHO on November 26, 2021 [16] . Currently, Omicron variant of SARS-CoV-2 has caused rapid epidemic expansion in many countries [17] [18] [19] [20] . Specially, the mutational sites of receptor binding domain (RBD) regions in Omicron variant leads to its widespread escape from the responses of neutralizing antibodies [21] [22] [23] [24] . Although vaccines theoretically prevent the transmission and infection of SARS-CoV-2 and are considered by the many to be the ultimate weapon against COVID-19 [14, [25] [26] [27] [28] , an increasing number of confirmed COVID-19 patients are alarmingly also vaccinated [15, [29] [30] [31] . Besides, some adverse reactions are reported in individuals vaccinated against COVID-19 [32] , including myocarditis [33] [34] [35] [36] , thrombosis [37] [38] [39] [40] [41] , adenopathy [42] [43] [44] , abnormal cutaneous manifestations [45] [46] [47] , and so on. Therefore, current circumstances indicate that there is still a long way to go to overcome COVID-19. As the causative agent for COVID-19, SARS-CoV-2 is a new type of β-coronavirus (β-CoV) with a genome of about 30 kb and encodes at least 29 proteins [48] [49] [50] . The recent outbreaks of two viral pneumonia induced by β-CoVs infection are SARS-CoV in 2002 [51] and MERS-CoV in 2012 [52] , respectively. Angiotensin-converting enzyme 2 (ACE2) is considered to be the common receptor for the cell entry of SARS-CoV and SARS-CoV-2 by binding to their surface spike (S) glycoprotein [53] [54] [55] while dipeptidyl peptidase 4 (DPP4) is the receptor for MERS-CoV-2 entry into cells [56] [57] [58] . In this case, DPP4 is considered as a potential receptor to binding the Spike protein of SARS-CoV-2 [59, 60] . Of note, a molecular docking study showed that the RBD of spike in SARS-CoV-2 had weakened interactions with DPP4 compared to MERS-CoV [61] , indicating DPP4 was not a dominant receptor for SARS-CoV-2. Recently, numerous excellent reviews and comments related to COVID-19 have been published [62] [63] [64] [65] [66] [67] [68] [69] , including the methods for medical and laboratorial diagnosis [70] [71] [72] [73] [74] [75] , the transmission and epidemiology [76] [77] [78] [79] , the potential pathological mechanisms and clinical manifestations [80] [81] [82] [83] [84] [85] [86] , the potential therapeutic strategies and management [87] [88] [89] [90] [91] [92] [93] . Excitingly, Dacheng Wei et al. developed a rapid and ultrasensitive method for the detection of SARS-CoV-2 [94] , which just need 4 min and detected an ultralow concentration (one to ten copies in 100 μL biofluids). Notably, some experts thought that omicron variant of SARS-CoV-2 may overturn the COVID-19 pandemic based on its genetic mutation and clinical peculiarities [95] [96] [97] . Instead, the other thought that we need to face a grim reality for COVID-19 caused by omicron variant due to its rapid spread and evasion from the immune response [98] [99] [100] [101] [102] [103] . Besides, most researches on the potential mechanisms underlying COVID-19 focus on the way for SARS-CoV-2 entry into host cells [104] [105] [106] [107] , the nonspecific and specific immune responses to SARS-CoV-2 infection [107] [108] [109] [110] [111] [112] , and the pathological consequences caused by SARS-CoV-2 infection [113] [114] [115] [116] [117] . However, there are still some important and fundamental scientific issues to be resolved. For instance, what are the vital pathogenic factors derived from SARS-CoV-2 for causing COVID-19? What is the material foundation of clinical manifestations of COVID- 19? It is well-known that β-CoVs replicate in doublemembrane vesicles (DMVs) of cell cytoplasm [118] [119] [120] [121] . Paulina Pawlica et al. found that SARS-CoV-2 could generate microRNA-like small RNA to silence host transcripts in cytoplasm and thus contribute to its pathogenesis [122] . However, recent researches indicated that SARS-CoV-2 RNA could be located in the host mitochondria and nucleolus [123, 124] . Moreover, numerous unknown transcripts of SARS-CoV-2 in infected Vero cells have been identified [125, 126] . Significantly, SARS-CoV-2 infection could cause human death even though it is not fatal to its potential hosts, including bats and pangolins [127, 128] . Frankly speaking, little is known regarding the function of SARS-CoV-2 RNA located in nucleus and the key factors involved in determining its pathogenicity in hosts. The recent research revealed that Human Identical Sequences of SARS-CoV-2 (HIS-SARS2) can promote COVID-19 progression by inducing hyaluronan accumulation through activating HAS2 expression [129] , which offers a novel insight into understanding the pathogenic mechanism of SARS-CoV-2. To date, complete recovery from COVID-19 is still not optimistic despite the tremendous efforts that have been made. Based on previous literature and our understanding of COVID-19, this review discusses pertinent topics of public concern and provides an intensive exposition on SARS-CoV-2, especially with regards to the pathogenic mechanism and potential therapeutic strategies. The basic reproduction number R nought (R0), also called the basic reproductive ratio, refers to the average number of secondary infected individuals directly linked to the primary infected individual [130, 131] . Generally, R0 is applied to evaluate the spread ability of communicable diseases, which indicates the intensity of infection and transmission for the infectious source (such as viruses and bacteria). Compared with the R0 (2 to 5) of severe acute respiratory syndrome coronavirus (SARS) outbreak in 2003, the R0 of COVID-19 caused by SARS-CoV-2 reached 1.5 to 6.49 [132, 133] . Remarkably, the mean R0 (5.08) of Delta variant is much higher than the R0 (2.79) of its ancestral strain [134] , indicating the high communicability of COVID-19. Currently, the Omicron variant has rapidly became a dominating variant of SARS-CoV-2 instead of Delta variant [135] . Which factors then determine the infection and transmission of SARS-CoV-2? The cell entry of SARS-CoV-2 is reported to be dependent on the ACE2 receptor with the help of TMPRSS2 [136] [137] [138] . Especially, the affinity between the S protein of SARS-CoV-2 and ACE2 receptor is 10-20 times that of SARS-CoV-1 [139] [140] [141] , which gives the susceptibility SARS-CoV-2 needs to invade cells. Surprisingly, the expression of ACE2 is upregulated in the lungs of patients with severe COVID-19 [142] [143] [144] . Consistent with this finding, HIS of SARS-CoV-2 can stimulate ACE2 expression [129] , implying that SARS-CoV-2 can promote cell entry through upregulating receptor expression by itself. As one of the glycans, heparan sulfate can interact with the RBD of the SARS-CoV-2 S glycoprotein to facilitate the binding of S protein to ACE2 [145] . Consist with this result, the infection of SARS-CoV-2 pseudovirus is significantly decreased in 293 T-hACE2 cells after treatment with heparin [146] . Noteworthily, SARS-CoV-1 and MERS-CoV can also utilize glycans mediated by their initial attachment to the host cell membranes [147, 148] , indicating the importance of glycans in virus infection. Interestingly, endothelial cells can be infected by SARS-CoV-2 only with a high viral load [149] . Moreover, the diversity of receptors facilitates their facile invasion into cells (Fig. 1) , such as ACE2 [136] , NRP1 [150] , CD147 [151] , and L-SIGN [152] . As one of the RNA viruses, the emergence of variants also enhances their high infectivity. For example, the widespread transmission of G614 variants in Europe and America is 3-9 times higher than that of the original D614 strain [153] . The re-positive cases of COVID-19 are usually defined as confirmed cases with SARS-CoV-2 infection after discharge. Different cohort studies have shown that the repositive ratio of SARS-CoV-2 ranges from 2.4% to 69.2% [154] [155] [156] [157] [158] . Notably, most re-positive cases are asymptomatic or mild after discharge [154, 155, 159] . Moreover, the re-positive cases tend to be younger populations, given its median average age at 28 years old [156] . Additionally, the viral load of SARS-CoV-2 was very low in the re-positive cases, as is their transmission risk [158, 159] . From these characteristics of re-positive cases, we speculated that a small amount of SARS-CoV-2 is still residual in the epithelial cells of the nasopharynx even if the clinical symptoms of COVID-19 have receded after treatment. In other words, the patients of re-positive cases had always carried SARS-CoV-2 rather than being truly "re-positive. " This gap in knowledge can be caused by Fig. 1 The model of SARS-CoV-2 entry into host cells. SARS-CoV-2 could initiate its attachment to the host cell membrane using the glycans (such as hyaluronan and heparan sulfate). Then, the interaction between spike glycoprotein and diverse receptors gives the susceptibility SARS-CoV-2 needs to invade host cells. Notably, hyaluronan is universal in the extracellular matrix of different cells, which may explain the infection of SARS-CoV-2 into cells only with a high viral load the limited sensitivity of current detection methods for SARS-CoV-2. Notably, the re-positive appearance of SARS-CoV-2 may hint at the "friendship" between SARS-CoV-2 and the epithelial cells of the nasopharynx. It is well-known that influenza viruses can disrupt the mucosal barrier resulting in coinfection with common strains of bacteria [160] [161] [162] , indicating that influenza viruses may cause damage to epithelial cells in the respiratory tract. However, the rate of COVID-19 cases with coinfection of bacteria is considerably low [163] [164] [165] [166] , further supporting the "friendship" between SARS-CoV-2 and the epithelial cells of the nasopharynx. Accordingly, one of the most common symptoms of COVID-19 is dry cough without sputum [167] [168] [169] , which has been used to accurately diagnose COVID-19 via artificial intelligence [48] . The hyperactive immune responses in COVID-19 patients promote the release of a large number of proinflammatory cytokines and further stimulate excessive inflammatory reaction, also known as the cytokine storm [170] , which induces acute respiratory distress syndrome (ARDS). It is reported that high concentrations of cytokines(such as IL-1β, TNFα, IL-6, and IL-8) and chemokines (such as CCL2, CCL-5, IFNγ-induced protein 10 (IP-10), and CCL3) are detected in plasma and BALF and are associated with the occurrence and poor clinical outcomes of ARDS, such as mortality rate [171] [172] [173] [174] [175] [176] . Apoptosis and other type of cell deaths could be another factors to cause ARDS, which has been reviewed in detail elsewhere [177] . For example, apoptosis mediated by the activation of Fas/Fas ligand pathway contributes to ARDS [178] [179] [180] . Currently, many systematic reviews have concentrated on cytokine storm in COVID-19 and discussed its potential mechanisms including signaling pathways [181] [182] [183] [184] [185] [186] [187] , which mainly emphasized the important roles of immune cells in cytokine storm. However, it isn't still clearly elucidated about the pathogenesis of cytokine storm. In the following section, we will discuss the distinct perspectives on the underlying mechanisms for cytokine storm in COVID-19 based on current clinical observations and experimental findings. The aberrant cutaneous manifestations in COVID-19 has been found in a multitude of retrospective studies [188] [189] [190] , such as the erythematous rash, urticaria and maculopapular eruptions, which are also the typical symptoms of allergic reactions. It is well-known that abnormal levels of IgE and histamine are universal indicators to assess allergic reactions [191] [192] [193] . In a retrospective study on COVID-19 [194] , the level of IgE is significantly increased in non-survivors (71.30 IU/mL), compared to survivors (42.25 IU/mL). Similarly, 119 of 303 (39%) COVID-19 patients with elevated serum IgE [195] . Particularly, the dynamic change of IgE is closely similar to IgM against SARS-CoV-2 [196] . Some excellent reviews have recently highlighted the importance of histamine and its receptors in COVID-19 [197, 198] . Particularly, SARS-CoV-2 could activate mast cells to secrete histamine [199] . At present, there are four known receptors of histamine, designated as H1/H2/H3/H4 receptors (H1R/H2R/H3R/ H4R). Although H1 and H2 receptors are relevant to allergic inflammation and gastric acid secretion, respectively [200] , both antagonists of H1R and H2R are therapeutic agents for acute allergic reactions in a clinical set [201] . Excitingly, the antagonists of H1/H2 receptor have been proven to improve outcomes of COVID-19 [198, 202] . Above all, allergic responses could appear in some COVID-19 patients, which were potentially elicited by SARS-CoV-2 infection. In this case, what are the potential allergens in COVID-19 after SARS-CoV-2 infection? Here, the S protein of SARS-CoV-2 may have a potential role as an allergen by analyzing the phenotype and potential molecular mechanisms after vaccination. Since the beginning of COVID-19 outbreak, the spike protein of SARS-CoV-2 has been considered as a foremost target for COVID-19 vaccine development. For example, one of the nCoV-19 vaccines, ChAdOx1, is a full-length virus vector of S-protein [203] . The occurrence of thrombocytopenia and thrombosis in individuals after ChAdOx1 vaccination has attracted public attention [204, 205] . In particular, survivors are discharged from the hospital on day 12 after prednisolone treatment [205] , a typical drug used for allergic diseases. Besides, anti-spike binding was detectable in all these individuals while the levels of antibodies against the S protein are varied [205] , suggesting the S protein was produced alongside the emergence of the syndrome. Another nCoV-19 vaccine, NVX-CoV2373 is a recombinant nanoparticle vaccine containing the trimeric full-length spike glycoproteins of SARS-CoV-2 (rSARS-CoV-2) and Matrix-M1 adjuvant [206] . During the phase 1-2 trial of NVX-CoV2373, only vaccination of 25 μg rSARS-CoV-2 can induce some mild symptoms after the second dose of vaccination including erythema, redness, induration, or swelling [206] , which provides direct evidence for the S protein as an allergen. In line with these findings, the safety assessment on the COVID-19 mRNA vaccine showed that the suspected adverse reactions primarily occurred after the second dose of COVID-19 vaccination [207] . Surprisingly, the spike protein of SARS-CoV-2 could directly induce the release of proinflammatory cytokines (such as TNFα) and apoptosis in THP-1-like macrophages [208] , indicating that S protein may serve as a pathogenic substance. Moreover, the S protein accelerated the expression of pro-thrombotic molecules in pulmonary endothelial cells [209] , further hinting the pathogenicity of S protein. Notably, a recent work found that high-sulfated hyaluronan could inactivate SARS-CoV-2 including Alpha and Beta variants by stable binding [210] , emphasizing the interaction between hyaluronan and SARS-CoV-2. The structure of monomers is similar between hyaluronan and heparin. Given that heparan sulfate can steadily bind to the RBD of S proteins [145] , there could be a similar interaction between hyaluronan and the S protein. Alarmingly, some individuals with hyaluronan dermal fillers had hypersensitivity reactions after SARS-CoV-2 infection or COVID-19 vaccination [211] [212] [213] [214] [215] [216] [217] , indicating the combination of hyaluronan and S protein may trigger the allergic reactions. Besides, COVID-19 vaccination led a distinct hepatitis mediated by CD8 T cell-dominant immune [218] , which may attribute to the long-term expression of S protein from the mRNA vaccination. Interestingly, the binding of hyaluronan to CD44 could regulate the CD8 T cell response [219] , further suggesting that the complex of hyaluronan and S protein may induce the hepatitis in individuals after COVID-19 vaccination. Collectively, all these signs suggest that the S protein of SARS-CoV-2 could serve as allergen and cause the allergic response in certain patients, further aggravating their COVID-19 symptoms or inducing adverse reactions toward vaccination. At present, symptomatic supportive treatment is still the primary therapeutic strategy for COVID-19 clinically [62] . Many potential therapeutic strategies have been proposed to combat COVID-19 [220] [221] [222] [223] [224] [225] [226] [227] [228] [229] , such as antiviral treatment, immunological therapy, Chinese medicinal therapy, and anti-inflammatory therapy. Interestingly, electric stimulation may be a subsidiary approach to improve COVID-19 outcomes by increasing the penetration of antiviral drugs [230] . Recently, these therapeutics for COVID-19 have been well-summarized in an updated review [231] . Given the emergency circumstances of COVID-19, some drugs have been urgently approved for COVID-19 treatment (Table 1) , which still need further clinical trials to confirm their effectiveness. The development of vaccines against SARS-CoV-2 is considered a key approach to fighting the COVID-19 outbreak. As of April 23, 2022, 153 COVID-19 vaccine candidates are in human clinical trials while 197 COVID-19 vaccine candidates are in preclinical development [232] . Numerous clinical trials of potential therapeutic drugs on COVID-19 are ongoing in the world. Yet unfortunately, there are still few drugs available for COVID-19 treatment in clinical practice other than dexamethasone, which promotes us to further investigate the pathogenic mechanism of COVID-19 and develop new therapeutic strategies. It is well known that protein encoded from the virus genome is the main driving factor in virus infection and disease development. Since the virus also contain nuclear acid, it would be interesting to investigate whether nuclear acid, especially in its non-coding regions, can also act as a pathogenic factor in virus infection, especially for SARS-CoV-2. Human Identical Sequences of SARS-CoV-2 (HIS-SARS2) are greater than 20 bp and are entirely identical sequences between SARS-CoV-2 and human genomes [129] . They function as miRNA-like RNA. Intriguingly, it has been reported that multiple viruses could produce miRNA-like non-coding RNAs during their infection [265] [266] [267] [268] [269] . For instance, the small viral RNAs (svRNAs) encoded by SARS-CoV could repress host mRNA expression by targeting 3′-UTR of specific transcripts [270] . Specially, SARS-CoV-2 can generate viral miRNAs in relation to the cellular metabolism and biosynthesis in host cells [271] . Recently, a noncoding RNA produced from the ORF7a in SARS-CoV-2 genome was demonstrated to decrease the host transcripts (such as BATF2) via target slicing [122] . Inversely, HIS-SARS2 could activate gene expression by targeting enhancer in human [129] , which significantly overlap with the aberrant expressed genes found in bronchoalveolar lavage fluid (BALF) of COVID-19 patients [272] . Particularly, HIS-SARS2 could upregulate inflammation-associated genes in transformed human embryonic kidney cell HEK293T, human fetal lung fibroblast cell MRC5, and human umbilical vein endothelial cell (HUVEC), which is consistent with the finding that the infection of SARS-CoV-2 could lead to multiple organ damage (such as lung, kidney, and liver) by stimulating an inflammation response [273] [274] [275] [276] . Moreover, HIS-SARS2 destroyed the function of mitochondria by increasing CYB5A and TIMM21, which may cause the mitochondria dysfunction related to COVID-19 pathogenesis [277] [278] [279] [280] . Moreover, the major enzyme for hyaluronan synthesis, HAS2, was activated by HIS-SARS2, which promoted hyaluronan accumulation in severe COVID-19 patients [129, 281, 282] . Notably, SARS-CoV-2 RNA was detected in the plasma of COVID-19 patients using droplet-based digital PCR [283] , raising a possibility that HIS-SARS2 could be transported into the distal cells and via hematologic system. Therefore, HIS-SARS2 exert an important role in the pathogenicity of SARS-CoV-2 during infection (Fig. 2) . Strikingly, SARS-CoV-2 infection does not affect the health of bats and pangolins [127, 128] . Some identical sequences were also found between SARS-CoV-2 and its potential hosts' genomes, which were termed as "Host Identical Sequences (HIS)", while no identical sequences were identified between the genome of SARS-CoV-2 and chicken. This indicates that HIS from SARS-CoV-2 may be helpful when tracing to its mediated hosts. Most importantly, we put forward the hypothesis of nucleic acid pathogenicity based on the discovery of HIS, which is that the identical sequences between the genome of viruses and hosts (such as human) probably [263, 264] hold the key for viruses to infect hosts and cause diseases. In fact, there are also identical sequences between the genome of human and other pathogenic viruses, including HIV, Ebolavirus, and Zika virus [129] , which provide additional support for our hypothesis. The HIS in different viruses deserve further efforts toward clarifying their potential functions, such as acting as important therapeutic targets for these associated diseases. As we all know, the immune responses divide into innate and adaptive responses, which are indisputably activated by SARS-CoV-2 infection in COVID-19. Particularly, the adaptive immune response is believed to be the most potent approach to clearing SARS-CoV-2 [110, [284] [285] [286] , which is contradictory to a recent report that no IgG antibody against SARS-CoV-2 is detected in 18% of COVID-19 patients even though the average testing time between IgG positive and negative groups is close [287] . Moreover, COVID-19 patients with the second infection have more severe clinical presentation than their first infection [288] [289] [290] , indicating that adaptive immune response may not exert a dominant role in combating SARS-CoV-2. In fact, many individuals with SARS-CoV-2 infection are capable of clearing the virus under asymptomatic situations [291] [292] [293] , which implies that innate immunity may hold the key to defeating SARS-CoV-2 as the first defense line against environmental pathogenic substances. In addition, different single-cell omics analyses of COVID-19 patients suggest that the cellular components of innate immune (such as macrophages and monocytes) could determine COVID-19 severity [294, 295] . Thus, innate immunity may play a dominant role in responding to SARS-CoV-2 infection rather than adaptive immunity during the COVID-19 process, which could be harnessed to mitigate COVID-19. Currently, it is a common consensus that various cytokines in COVID-19 are generated by diverse immune cells involved in innate immunity (such as neutrophils and macrophages) and adaptive immunity (such as adaptive B and T lymphocytes) [296] . There are many significant increases of cytokines in severe COVID-19 patients [296] [297] [298] , including TNFα, IL-6, IL-8, and IL-10. Honestly, we have unwittingly ignored that non-immune cells (such as endothelial cells and fibroblasts) can also produce cytokines [299, 300] , which may contribute to the cytokine storm in COVID-19. For example, pulmonary endothelial cells could produce IL-6 by sensing SARS-CoV-2 infection in the adjacent epithelium [149] . Similarly, HIS-SARS2 could activate inflammation-associated genes in human umbilical vein endothelial cells [129] . In line with these findings, circulating endothelial cells were significantly more relevant to IL-6 in severe COVID-19 patients [301] . Notably, fibroblasts could also produce pro-inflammatory cytokines and participate in the persistence of inflammation [302] , which may underly the multi-organ fibrosis of COVID-19 patients [303] . Especially, HIS-SARS2 could upregulate HAS2 in human fetal lung fibroblast cells and promote the synthesis of hyaluronan [129] , a crucial mediator for inflammation, which may be connected to the pulmonary fibrosis of COVID-19 [304] . Notably, the binding of hyaluronan to CD44 can induce the production of IL-6 and IL-8 in human dermal fibroblasts [305] . In addition, the interaction between hyaluronan and its receptors facilitates cytokine production (such as IL-6 and IL-8) in immune cells [306] [307] [308] , including macrophages, neutrophils, and dendritic cells. Together, these findings hint that With the help of AGO2, HIS could bind to their targeting enhancers in the human genome. Subsequently, the interaction between enhancer and RNA polymerase II (RNAP II) mediated-mediators will promote the transcription of inflammation-related genes in proximal or in distal cytokines released by non-immune cells may trigger cytokine storm in severe COVID-19 (Fig. 3) . Given that fibroblasts are widely distributed in various tissues and organs, we believe that fibroblasts may be a major source of cytokine in COVID-19. COVID-19 has various clinical symptoms. The most common symptoms of COVID-19 are fever, dry cough, and shortness of breath [167] . Based on chest CT, ground-glass opacity (GGO) or consolidations exist in the lungs of COVID-19 patients [309] . Lymphopenia and elevated C-reaction protein (CRP) are two of the most common laboratory abnormalities in hospitalized COVID-19 patients [310] . Meanwhile, severe COVID-19 patients develop ARDS [311] . Notably, COVID-19 can impair the function of multiple organs (such as heart, brain, lung, liver, and kidney) and the coagulation system [62] . Additionally, COVID-19 patients show some neurological complications and symptoms (such as headache, encephalitis, and intracerebral hemorrhage) [312] . However, the foundation underlying the clinical manifestations of COVID-19 is still ambiguous. Recently, a few studies on metabolic profiles have revealed that the metabolism of carbohydrates, fats, and proteins are dysregulated in COVID-19 patients [313] [314] [315] [316] [317] , which may provide us some important indication. Specially, gene alterations involved in the metabolism of hyaluronan, glycosaminoglycan, and mucopolysaccharides are excessive in SARS-CoV-2 infected bronchoalveolar cells [317] . In line with this finding, there is a significant increase of hyaluronan in patients with severe and critical COVID-19 [129, 281] , indicating that hyaluronan is related to the COVID-19 clinical process. According to the recent results combined with previous literature, hyaluronan may be crucial to the material foundation of COVID-19 clinical symptoms (Fig. 4) . GGO is a typical presentation of COVID-19 patients based on chest CT, which can further develop into consolidations. Autopsy from three patients with COVID-19 showed that hyaluronan is accumulated in the lung alveoli [318] . Similarly, hyaluronan is also abundant in the respiratory secretions of COVID-19 patients [319] . Strikingly, hyaluronan positively relates to the volume of extravascular water in normal animal lungs [320] , which may be due to its ability to absorb a large volume of water [321] . This water absorption characteristic of hyaluronan may be a cause for the jelly-like substance formation present in the lungs of severe COVID-19 patients [322] . Moreover, intratracheal instillation of hyaluronan directly causes pulmonary ground-glass opacity (GGO) or consolidations in mice [323] . Therefore, these evidences suggest that the GGO or consolidations in COVID-19 patients' lungs contribute to the increase in hyaluronan. Lymphocytopenia is a syndrome defined as the loss of lymphocyte in peripheral blood. The reduction of lymphocytes is revealed to be lower in COVID-19 patients with higher levels of hyaluronan [129] . The increased hyaluronan is positively related to the elevated CRP, but negatively related to decreased lymphocytes in COVID-19 patients, which may be due to the reduction in total T lymphocytes [324] . Intriguingly, the interaction between hyaluronan and its ligand CD44 can cause T cells death when they are activated [325] . In fact, the infection of SARS-CoV-2 can rapidly activate CD4+ T lymphocytes [326] . Thus, the reduction of T lymphocytes mediated by hyaluronan may underlie the foundation of lymphocytopenia in patients with COVID-19. ARDS is a clinical syndrome characterized by hypoxemia and nonhydrostatic pulmonary edema [327] , one of the leading causes of COVID-19 death. Generally, ARDS is thought to be the impairment of pulmonary vascular permeability, which increases lung mass as caused by acute diffuse inflammatory lung injury. Plenty of studies have revealed that hyaluronan can serve as an essential mediator for inflammation and vascular homeostasis [328, 329] , which may underlie the inflammatory and vascular permeability impairment in COVID-19 patients with ARDS. These insights are supported by the emergence of hyaluronan in the lung alveoli of patients with ARDS [318] . Especially, HIS-SARS2 can upregulate the expression of a key hyaluronan synthase HAS2 in MRC5 and HUVEC [129] , suggesting that the SARS-CoV-2 infection could directly induce hyaluronan accumulation in lungs. Consistent with these results, pulmonary microvascular endothelial cells could produce hyaluronan to directly destroy the endothelial barrier when they are exposed to the COVID-19 environment [330] . The binding of hyaluronan may mediate the disruption of endothelial cell barrier to its receptor HABP2 [331] . Hence, beyond triggering the pulmonary inflammatory, dysfunction of the pulmonary endothelial barrier induced by hyaluronan could account for ARDS. SARS-CoV-2 has been demonstrated to infect diverse cell types in different tissues [150, [332] [333] [334] , including lungs, kidneys, brain, and heart. Interestingly, hyaluronan is widely distributed in all parts of the body and exercises a myriad of biological functions in different cell types [335] . Particularly, HIS-SARS2 can induce hyaluronan production via stimulating HAS2 expression in diverse cells associated with lung, blood vessel, and kidney [17] , implying the inflammation trigged by hyaluronan may be the cause of multiple organ injury. In addition, 71% of 183 COVID-19 patients who passed away had diffuse intravascular coagulation [336] . Notably, HABP2, a receptor of hyaluronan is involved in blood coagulation [337] , which may also play a key role in the dysfunction of the coagulation system in response to the increased hyaluronan level in COVID-19 patients. Fig. 4 The potential relationships between hyaluronan and COVID-19. The infection of SARS-CoV-2 accelerates the production of hyaluronan in blood and lung in COVID-19 patients. The accumulation of hyaluronan in lung directly causes the ground-glass opacity, which further develops consolidation. Additionally, the plasma hyaluronan is closely related to other clinical symptoms including lymphocytopenia, cytokine storm, ARDS, multiple organ injury, and coagulation dysfunction. Notably, the most susceptible population of SARS-CoV-2 have a high level of plasma hyaluronan The case fatality rate (CFR) of COVID-19 worldwide in 219 countries is approximately 2.1% based on the WHO Coronavirus Dashboard by 22 August 2021. There are many risk factors (such as advanced age, diabetes, hypertension, and cancer) for COVID-19 mortality [338] . Specially, pregnant women and newborns are susceptible to SARS-CoV-2 and can develop severe COVID-19 [339, 340] . Additionally, there are some long-term sequelae of COVID-19 [341, 342] , such as severe fatigue, loss of sense of smell or taste, and skin rash. Of note, female sex and older age are related to the risk of persistent symptoms in long COVID [343] . However, the intrinsic relationship between COVID-19 and its risk factors are still unclear. Remarkably, hyaluronan could help explain the connection between COVID-19 and some of its risk factors. It is reported that serum hyaluronan level of newborns (0-7 day) and elderly people (>60 years) are higher than the other ages in 585 healthy individuals [344] . The higher level of hyaluronan could be associated with the risk of long-term sequelae of COVID-19 in older people. Similarly, the serum hyaluronan level in diabetic patients (83.6 ± 5.6 ng/mL) was significantly higher than in normal subjects (41.7 ± 12 ng/mL) [345] . In addition, the elevation of plasma hyaluronan was found in patients with pulmonary hypertension and cancer [346, 347] . Moreover, there is a gradual increase of serum hyaluronan level in women during pregnancy [348] , which may partly explain the higher probability of COVID-19 sequelae in female. And lastly, individuals who have received vaccination but died from COVID-19 did so from major cerebral hemorrhage [204] . All these individuals have a high level of platelet factor 4 (PF4). Notably, PF4 can stimulate the release of histamine from basophils and mast cells [349, 350] , which could further accelerate the hyaluronan synthesis [351] . Surprisingly, hyaluronan is capable of regulating vascular integrity [352] , which may caused the fatal intracranial hemorrhage in vaccinated individuals. Recently, it is reported that the hepatitis of unknown aetiology occurred in five young children infected with SARS-CoV-2 in Scotland [353] , which may be attributable to the accumulation of hyaluronan in liver [354] . Thus, we can reasonably infer that a high level of hyaluronan in these individuals may provoke a more violent response after SARS-CoV-2 infection, further exacerbating COVID-19 symptoms (Fig. 4) . Serum hyaluronan is usually a non-invasive test to diagnose liver cirrhosis [355] , which means that it is exceptionally convenient to detect hyaluronan in clinical. Combined with the potential roles of hyaluronan in COVID-19, hyaluronan may become a useful clinical indicator for COVID-19. For one, hyaluronan can predict the progression of COVID-19, which is helpful for physicians to determine which patients would require special attention. Secondly, hyaluronan can act as a biomarker to appraise the prognosis of COVID-19. And lastly, hyaluronan can initially screen individuals vaccinated against COVID-19, which may reduce adverse reactions in certain individuals. Here, we proposed three promising therapeutic agents for COVID-19 treatment on the basis of our recent studies and novel insights into COVID-19, including antisense oligonucleotides (ASOs) of HIS-SARS2, inhibitors of hyaluronan synthesis, and antiallergic agents (Fig. 5) . ASOs are defined as synthesized oligonucleotides measuring 12-30 nucleotides, which are designed to bind to RNA based on base pairing rules [356] . Along with the improvement in technology, ASOs have been used as a therapeutic drug since the late 1980s. To date, several ASO drugs have been approved by the Food and Drug Administration (FDA) to treat different diseases [357] . For example, a 30-mer morpholino ASO, eteplirsen obtained the provisional approval by FDA to treat Duchenne Muscular Dystrophy [358] . Notably, antisense morpholino oligomers targeting the transcription-regulatory sequence (TRS) regions of SARS-CoV could inhibit the production of SARS-CoV [359] . Similarly, the antisense peptide nucleic acid targeting the highly conserved PRF signal of SARS-CoV could significantly suppress its replication [360] . Recently, the importance of ASOs in combating COVID-19 have been recognized due to their high target specificity and rapid development [361] . Especially, the appearance of nanotechnology could facilitate the delivery of ASOs to their target sites [362] . However, it is crucial to identify the potential targets of SARS-CoV-2. The recent research has clarified the key roles of HIS-SARS2 in response to SARS-CoV-2 infection. In particular HIS-SARS2 upregulated genes associated with inflammation whereas their antagomirs abolished their activation [129] , suggesting the blocking of HIS-SARS2 could be conducive to alleviating the inflammatory response in COVID-19. Therefore, HIS-SARS2 are candidate targets when designing ASOs, which hold great potential in treating COVID-19. The concentration of hyaluronan is significantly higher in patients with severe COVID-19 [129, 281] . As mentioned above, elevated hyaluronan in COVID-19 could cause most clinical manifestations (such as GGO, lymphopenia, and ARDS) and establish a subtle connection with the risk factors, indicating that hyaluronan could be a key therapeutic target for COVID-19. In fact, this insight is also supported by certain medications for COVID-19 that have already been proven effective in clinical trials. Dexamethasone and Metformin are reported to significantly reduce the CFR of severe COVID-19 patients [363] [364] [365] , which may be partly attributed to their effects in rapid decrease of hyaluronan [366, 367] . Consequently, inhibitors of hyaluronan synthesis are promising therapeutic agents for COVID-19. 4-methylumbelliferone (4-MU) is a coumarin derivative that can suppress the hyaluronan synthesis by downregulating the mRNA levels of hyaluronan synthases and depleting their substrate UDP-glucuronic acid [368] . Fortunately, there is an approved prescription drug of 4-MU, called hymecromone, which is used for biliary spasm treatment [369] . In a small sample clinical trial, hymecromone has been verified to accelerate the recovery of COVID-19 patients via the promotion of lymphocyte recovery and pulmonary lesion absorption [323] . In other words, hymecromone could be an efficient clinical prescription to block COVID-19 progression. The elevation of serum IgE in COVID-19 patients indicates SARS-CoV-2 infection can stimulate an allergic reaction in some individuals. We proposed above that the S protein of SARS-CoV-2 may serve as an allergen to stimulate an allergic reaction. As such, antiallergic agents could be potential candidates for COVID-19. In general, common clinical antiallergics are antihistamines (such as Diphenhydramine, Promethazine, and Chlorpheniramine) and corticosteroids (such as Dexamethasone) [370, 371] . In addition, the monoclonal antibodies of anti-IgE are alternative agents for anaphylaxis [372] . These antiallergic agents may be new weapons against COVID-19. In order to end the COVID-19 pandemic, scientists around the world have conducted a great deal of research on SARS-CoV-2 since its initial outbreak. However, some important issues on the COVID-19 and SARS-CoV-2 are still waiting to be solved. Here, we summarized five concerned problems and discussed the possible answers based on the Three-H strategy. The potential strategies for COVID-19 therapy. There are two potential approaches to cause the clinical symptoms of COVID-19. In one hand, the generation of HIS from SARS-CoV-2 could activate inflammation-related genes (such as HAS2) and induce the production of hyaluronan. On the other hand, the spike protein of SARS-CoV-2 could trigger the allergic reaction in some individuals with COVID-19. Accordingly, we could use antisense oligonucleotides (ASOs) of HIS-SARS2, inhibitors of hyaluronan synthesis, and antiallergic agents to block these approaches and thereby facilitate the recovery of clinical symptoms in Why does the pathogenicity of SARS-CoV-2 have species specificity? The interaction between HIS-SARS2 and enhancer activates expression of genes associated with inflammation and further promotes the COVID-19 progression. The sequences of HIS-SARS2 showed the higher conservation in primates (such as Rhesus and Green monkey) [129] , which could explain the similar pulmonary damage to COVID-19 in rhesus macaques infected with SARS-CoV-2 [373] . Thus, the interaction between HIS-SARS2 and enhancer determines the pathogenicity of SARS-CoV-2 in specific species. Accordingly, primates could be the best choices to establish animal models of COVID-19 for mechanism research and drug development. What is the potential mechanism of the clinical manifestations (such as cytokine storm, GGO, thrombosis, and anosmia) in COVID-19? On one hand, HIS-SARS2 activates the expression of HAS2 and induces the accumulation of hyaluronan in the SARS-CoV-2 infected host cells through targeting enhancer. As the key inflammatory mediator, hyaluronan stimulates the non-immune cells (such as fibroblasts) to release cytokines. Meanwhile, the increased hyaluronan in lung leads to the GGO in COVID-19 patients. The binding of hyaluronan to its receptor HABP2 mediates the abnormal thrombosis, which may cause the anosmia in COVID-19 [374] . On the other hand, HIS-SARS2 may promote the production of hyaluronan in distal host cells without SARS-CoV-2 infection via the transportation in exosomes. In this situation, HIS-SARS2 may activate the release of cytokines in fibroblasts through the NamiRNA-Enhancer network. Why are the specific subpopulations (such as pregnant women, and elderly people, and male sex) susceptible to SARS-CoV-2? As one of the glycans, heparin in the surfaces of the cell facilitate the cell entry of SARS-CoV-2. Likewise, hyaluronan in the cell surfaces may stick SARS-CoV-2 and promote its infection. The pregnant women, and elderly people have higher hyaluronan level, which might enhance the invasion of SARS-CoV-2. Surprisingly, testosterone could elevate the expression of hyaluronan synthase 1 in fibroblasts [375] , suggesting that the androgen in the male sex may further increase the hyaluronan production and cause the susceptibility to SARS-CoV-2. How do we estimate the progression of COVID-19 and decrease the risk of severe COVID-19 in specific subpopulations (such as elderly people and diabetes patients)? Given that hyaluronan is closely associated with the progression of COVID-19 [281, 323] , the detection of plasma hyaluronan level may be an important approach to judge the COVID-19 progression. Moreover, hyaluronan level is relatively higher in elderly people and diabetes patients. After SARS-CoV-2 infection, the complexes of hyaluronan and S protein may together aggravate the COVID-19. Which are the novel strategies to develop the effective drugs for COVID-19 and prevent the sequelae of COVID-19? Focus on HIS and hyaluronan is one of the novel strategies for the drug development of COVID − 19. Specifically, we could design the ASO drugs targeting HIS and develop small molecular inhibitors against hyaluronan, which may block the interaction between SARS-CoV-2 and human. Similar, prevention of the hyaluronan elevation by inhibiting androgen pathway is also a strategy for the treatment of COVID-19. When it comes to the intervention therapy of COVID-19, the combination of diverse drugs (such as antiviral drugs and hymecromone) may reach a better therapeutical effect [376] . In addition, reduction of hyaluronan into the normal range might be a potential strategy to prevent the sequelae of COVID-19 though the oral administration of hyaluronan inhibitor drugs (such as hymecromone). Taken together, Three-H is crucial for us to reconsider the underlying relationship between COVID-19 and SARS-CoV-2. The oligonucleotide drugs, inhibitors of hyaluronan synthesis, or antiallergic agents deserve our time and effort towards further validating their effectiveness in treating COVID-19 in the future. Code availability Not applicable. Authors' contributions W.Y. and S.Y. discussed and proposed the outline of this reviews. S.Y., Y.T., and L.C. finished the manuscript. All the authors participated in manuscript revision and approved the final submission of this manuscript. Not applicable. Disease and healthcare burden of COVID-19 in the United States Assessing the burden of coronavirus disease 2019 (COVID-19) among healthcare workers in Mexico City: a data-driven call to action Effects of COVID-19 pandemic in daily life Risk and resilience in family well-being during the COVID-19 pandemic Towards effective COVID19 vaccines: updates, perspectives and challenges (review) The 2020 race towards SARS-CoV-2 specific vaccines Progress and prospects on vaccine development against SARS-CoV-2. Vaccines (Basel) Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression DNA based vaccine expressing SARS-CoV-2 spike-CD40L fusion protein confers protection against challenge in a Syrian hamster model DNA vaccines against COVID-19: perspectives and challenges Immunological considerations for COVID-19 vaccine strategies COVID-19 vaccines: modes of immune activation and future challenges SARS-CoV-2 DNA vaccine INO-4800 induces durable immune responses capable of being boosted in a phase 1 open-label trial The COVID-19 vaccine development landscape An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria SARS-CoV-2 omicron variant: characteristics and prevention Rapid epidemic expansion of the SARS-CoV-2 omicron variant in southern Africa Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic Transmission of omicron (B.1.1.529) -SARS-CoV-2 variant of concern in a designated quarantine hotel for travelers: a challenge of elimination strategy of COVID-19 SARS-CoV-2 omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses Omicron, the great escape artist Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies Considerable escape of SARS-CoV-2 omicron to antibody neutralization COVID-19 vaccines Vaccines for COVID-19 Ensuring global access to COVID-19 vaccines: deployment strategies for refugees and migrants must not be forgotten Ensuring global access to COVID-19 vaccines COVID-19 vaccine and death: causality algorithm according to the WHO eligibility diagnosis. Diagnostics (Basel) COVID-19 vaccine breakthrough infections reported to CDC-United States Population immunity and Covid-19 severity with omicron variant in South Africa Adverse reactions to COVID-19 vaccines: a practical approach Myocarditis after Covid-19 mRNA vaccination Myocarditisinduced sudden death after BNT162b2 mRNA COVID-19 vaccination in Korea: case report focusing on histopathological findings Myocarditis and pericarditis after Covid-19 mRNA vaccination: practical considerations for care providers Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from Cutaneous thrombosis associated with skin necrosis following Oxford-AstraZeneca COVID-19 vaccination Thrombosis after covid-19 vaccination Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis Deep vein thrombosis more than two weeks after vaccination against COVID-19 Thrombosis after adenovirusvectored COVID-19 vaccination: a concern on underlying illness Adenopathy following COVID-19 vaccination Lymphadenopathy following COVID-19 vaccination: imaging findings review Regional lymphadenopathy following COVID-19 vaccination: literature review and considerations for patient management in breast cancer care Cutaneous findings following COVID-19 vaccination: review of world literature and own experience Cutaneous adverse reactions associated with SARS-CoV-2 vaccines Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit? Molecular architecture of the SARS-CoV-2 virus The proximal origin of SARS-CoV-2 The UCSC SARS-CoV-2 genome browser A decade after SARS: strategies for controlling emerging coronaviruses Middle East respiratory syndrome Coronavirus disease 2019 (COVID-19): current status and future perspectives Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2 ACE2: from vasopeptidase to SARS virus receptor SARS and other coronaviruses as causes of pneumonia Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4 Adaptive evolution of MERS-CoV to species variation in DPP4 The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. iScience A novel purification procedure for active recombinant human DPP4 and the inability of DPP4 to bind SARS-CoV-2 Does the SARS-CoV-2 spike protein receptor binding domain interact effectively with the DPP4 (CD26) receptor? A molecular docking study Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review Coronavirus disease 2019 (COVID-19): An overview of the immunopathology, serological diagnosis and management Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis Coronavirus disease (COVID-19): reviews, applications, and current status A systematic review of systematic reviews on the COVID-19 pandemic Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic Human genetics of SARS-CoV-2 infection and critical COVID-19 Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls Publishing Diagnosis of COVID-19 for controlling the pandemic: a review of the state-of-the-art COVID-19 diagnosis -a review of current methods A comprehensive review on current COVID-19 detection methods: from lab care to point of care diagnosis Laboratory testing for the diagnosis of COVID-19 Current practice and potential strategy in diagnosing COVID-19 Diagnosing COVID-19 in the emergency department: a scoping review of clinical examinations, laboratory tests, imaging accuracy, and biases COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics COVID-19: a global challenge with old history, epidemiology and progress so far Reproduction numbers of SARS-CoV-2 variants: a systematic review and meta-analysis Infection prevention during the coronavirus disease 2019 pandemic SARS-CoV-2-specific immune response and the pathogenesis of COVID-19 Sexual dimorphism in COVID-19: potential clinical and public health implications Pathological sequelae of long-haul COVID The unfavorable clinical outcome of COVID-19 in smokers is mediated by H3K4me3, H3K9me3 and H3K27me3 histone marks. Epigenomics COVID-19: systemic pathology and its implications for therapy The probable role and therapeutic potential of the PI3K/AKT signaling pathway in SARS-CoV-2 induced coagulopathy Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy Endothelial dysfunction in COVID-19: a unifying mechanism and a potential therapeutic target Microbiome modulation as a novel strategy to treat and prevent respiratory infections COVID-19: characteristics and therapeutics Emerging treatment strategies for COVID-19 infection COVID-19 diagnosis and management: a comprehensive review Cell-free DNA: potential application in COVID-19 diagnostics and management Mutational pattern, impacts and potential preventive strategies of omicron SARS-CoV-2 variant infection Rapid and ultrasensitive electromechanical detection of ions, biomolecules and SARS-CoV-2 RNA in unamplified samples Omicron genetic and clinical peculiarities that may overturn SARS-CoV-2 pandemic: a literature review Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics SARS-CoV-2 omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells Literature review of omicron: a grim reality amidst COVID-19. Microorganisms Heavily mutated omicron variant puts scientists on alert Omicron likely to weaken COVID vaccine protection Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine SARS-CoV-2 omicron variant: a next phase of the COVID-19 pandemic and a call to arms for system sciences and precision medicine The significant immune escape of pseudotyped SARS-CoV-2 variant omicron CD147-spike protein interaction in COVID-19: get the ball rolling with a novel receptor and therapeutic target Can SARS-CoV-2 virus use multiple receptors to enter host cells? COVID-19 and genetic variants of protein involved in the SARS-CoV-2 entry into the host cells Mechanisms of SARS-CoV-2 entry into cells The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals Evolution of immune responses to SARS-CoV-2 in mild-moderate COVID-19 Peculiarities of the T cell immune response in COVID-19. Vaccines (Basel) Neuroinvasion of SARS-CoV-2 in human and mouse brain Cytokine storm and leukocyte changes in mild versus severe SARS-CoV-2 infection: review of 3939 COVID-19 patients in China and emerging pathogenesis and therapy concepts COVID-19: from an acute to chronic disease? Potential long-term health consequences SARS-CoV-2 infects human pancreatic beta cells and elicits beta cell impairment SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals A unifying structural and functional model of the coronavirus replication organelle: tracking down RNA synthesis Membrane binding proteins of coronaviruses Membrane remodeling by SARS-CoV-2 -doubleenveloped viral replication Double-membrane vesicles as platforms for viral replication SARS-CoV-2 expresses a microRNA-like small RNA able to selectively repress host genes RNA-GPS predicts SARS-CoV-2 RNA residency to host mitochondria and nucleolus SARS-CoV-2 infection triggers widespread host mRNA decay leading to an mRNA export block The architecture of SARS-CoV-2 transcriptome SARS-CoV-2: from its discovery to genome structure, transcription, and replication Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins A pneumonia outbreak associated with a new coronavirus of probable bat origin SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network The estimation of the basic reproduction number for infectious diseases Complexity of the basic reproduction number (R0) The reproductive number of COVID-19 is higher compared to SARS coronavirus High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2 The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus 2 (B.1.1.529.2): high potential to becoming the next dominating variant SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies ACE2 and TMPRSS2 are expressed on the human ocular surface, suggesting susceptibility to SARS-CoV-2 infection Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation Dynamics of the ACE2-SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms ACE2: the molecular doorway to SARS-CoV-2 ACE2 expression is increased in the lungs of patients with comorbidities associated with severe COVID-19 ACE2 elevation in severe COVID-19 ACE2: the key molecule for understanding the pathophysiology of severe and critical conditions of COVID-19: demon or angel? Viruses SARS-CoV-2 infection depends on cellular heparan sulfate and ACE2 Inhaled heparin polysaccharide nanodecoy against SARS-CoV-2 and variants Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein Endothelial cells elicit a pro-inflammatory response to SARS-CoV-2 without productive viral infection Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity SARS-CoV-2 pseudovirus enters the host cells through spike protein-CD147 in an Arf6-dependent manner L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus Prevalence and outcomes of re-positive nucleic acid tests in discharged COVID-19 patients Rate of re-positive RT-PCR test among patients recovered from COVID-19 Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR South Korea's COVID-19 infection status: from the perspective of re-positive test results after viral clearance evidenced by negative test results Low infectious risk of re-positive COVID-19 patients: a single-center study Reinfection or reactivation of severe acute respiratory syndrome coronavirus 2: a systematic review Why is coinfection with influenza virus and bacteria so difficult to control The co-pathogenesis of influenza viruses with bacteria in the lung The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis. Influenza Other Respir Viruses Low rate of bacterial co-infection in patients with COVID-19 National surveillance of bacterial and fungal coinfection and secondary infection in COVID-19 patients in England: lessons from the first wave Characteristics of COVID-19 patients with bacterial coinfection admitted to the hospital from the emergency department in a large regional healthcare system Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis Symptom criteria for COVID-19 testing of heath care workers Main symptoms in patients presenting in the COVID-19 period The COVID-19 cytokine storm; what we know so far Biomarkers of inflammation, coagulation and fibrinolysis predict mortality in acute lung injury National Heart LBIARD-SCTN. Elevated plasma levels of soluble TNF receptors are associated with morbidity and mortality in patients with acute lung injury Proinflammatory activity in bronchoalveolar lavage fluids from patients with ARDS, a prominent role for interleukin-1 Human immunopathogenesis of severe acute respiratory syndrome (SARS) Characterization of cytokine/chemokine profiles of severe acute respiratory syndrome Expression profile of immune response genes in patients with severe acute respiratory syndrome Acute lung injury and cell death: how many ways can cells die? Fas and fas ligand are up-regulated in pulmonary edema fluid and lung tissue of patients with acute lung injury and the acute respiratory distress syndrome Upregulation of two death pathways of perforin/granzyme and FasL/Fas in septic acute respiratory distress syndrome The Fas/FasL pathway impairs the alveolar fluid clearance in mouse lungs The cytokine storm and COVID-19 Immunopathogenesis and treatment of cytokine storm in COVID-19 The pathogenesis and treatment of the `cytokine Storm' in COVID-19 Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment The role of cytokines and chemokines in severe acute respiratory syndrome coronavirus 2 infections T cell immunobiology and cytokine storm of COVID-19 COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons Cutaneous manifestations in COVID-19: a first perspective Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Cutaneous manifestations related to coronavirus disease 2019 (COVID-19): a prospective study from China and Italy The biology of IGE and the basis of allergic disease The basics of histamine biology Clinical characteristics of 182 pediatric COVID-19 patients with different severities and allergic status Abnormal immunity of non-survivors with COVID-19: predictors for mortality Comparative analysis of clinical characteristics, imaging and laboratory findings of different age groups with COVID-19 Dynamic monitoring of immune function indexes in COVID-19 patients Histamine receptors and COVID-19 Could histamine H1 receptor antagonists be used for treating COVID-19? Mast cells activated by SARS-CoV-2 release histamine which increases IL-1 levels causing cytokine storm and inflammatory reaction in COVID-19 Histamine pharmacology: from sir Henry dale to the 21st century Anaphylactic responses to histamine in mice utilize both histamine receptors 1 and 2 Dual-histamine receptor blockade with cetirizine -famotidine reduces pulmonary symptoms in COVID-19 patients Progress in research on the S protein as the target of COVID-19 vaccines Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Phase 1-2 trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine Safety of COVID-19 vaccines administered in the EU: should we be concerned? SARS-CoV-2 coronavirus spike protein-induced apoptosis, inflammatory, and oxidative stress responses in THP-1-like-macrophages: potential role of angiotensin-converting enzyme inhibitor (perindopril) SARS-CoV-2 spike protein 1 activates microvascular endothelial cells and complement system leading to platelet aggregation Highsulfated glycosaminoglycans prevent Coronavirus replication Hypersensitivity reaction to hyaluronic acid dermal filler following novel coronavirus infection -a case report Hypersensitivity reaction to hyaluronic acid dermal filler after COVID-19 vaccination: a series of cases in Sao Paulo, Brazil Hypersensitivity reaction to hyaluronic acid dermal filler after the Pfizer vaccination against SARS-CoV-2 Increase in the incidence of acute inflammatory reactions to injectable fillers during COVID-19 era Hyaluronic acid delayed inflammatory reaction after third dose of SARS-CoV-2 vaccine COVID-19 vaccine in patients with dermal hyaluronic acid fillers in the tear trough: a retrospective study Delayed inflammatory reaction to dermal fillers after COVID-19 vaccination: a case report SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis Hyaluronan binding function of CD44 is transiently activated on T cells during an in vivo immune response Emerging therapeutic strategies for COVID-19 patients COVID-19 transmission, current treatment, and future therapeutic strategies Anti-SARS-CoV-2 strategies and the potential role of miRNA in the assessment of COVID-19 morbidity, recurrence, and therapy Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections Traditional Chinese medicine treatment of COVID-19 Can bilirubin nanomedicine become a hope for the management of COVID-19? Med Hypotheses Decorin as a possible strategy for the amelioration of COVID-19 Silver nanoparticle based multifunctional approach for combating Allium sativum derived carbon dots as a potential theranostic agent to combat the COVID-19 crisis Potential of electric stimulation for the management of COVID-19 Therapeutics for COVID-19 and post COVID-19 complications: an update World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines Remdesivir for 5 or 10 days in patients with severe Covid-19 Effect of Remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial Baricitinib plus remdesivir for hospitalized adults with Covid-19 Remdesivir for the treatment of Covid-19 -final report SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 A narrative review of the clinical practicalities of bamlanivimab and etesevimab antibody therapies for SARS-CoV-2 Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 Molnupiravir-a novel oral anti-SARS-CoV-2 agent Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients Infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus in symptomatic coronavirus disease 2019 (COVID-19) outpatients: host, disease, and viral correlates Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial The UPMC OPTIMISE-C19 (OPtimizing treatment and impact of monoclonal antIbodieS through evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization Effect of Bamlanivimab as monotherapy or in combination with Etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19 REGEN-COV antibody combination and outcomes in outpatients with Covid-19 REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19 Effect of subcutaneous Casirivimab and Imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial REGEN-COV((R)) antibody cocktail bioanalytical strategy: comparison of LC-MRM-MS and immunoassay methods for drug quantification Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19. medRxiv Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Treatment of severe COVID-19 with convalescent plasma in the Bronx Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19 Early convalescent plasma for high-risk outpatients with Covid-19 Treatment of coronavirus disease 2019 (COVID-19) patients with convalescent plasma A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19 Passive immunity trial for our nation (PassITON): study protocol for a randomized placebo-control clinical trial evaluating COVID-19 convalescent plasma in hospitalized adults Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19 Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2 Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects The interplay between viralderived miRNAs and host immunity during infection Viral non-coding RNAs: stealth strategies in the tug-of-war between humans and herpesviruses Role of noncoding RNAs in dengue virus-host interaction Non-coding RNAs and retroviruses Emerging roles of small Epstein-Barr virus derived non-coding RNAs in epithelial malignancy SARS-CoV-encoded small RNAs contribute to infection-associated lung pathology Viral micro-RNAs encoded by nucleocapsid gene of SARS-CoV-2 are detected during infection, and aargeting metabolic pathways in host cells Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients Clinical characterization and possible pathological mechanism of acute myocardial injury in COVID-19 Extrapulmonary manifestations of COVID-19 Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage Acute kidney injury (AKI) in patients with Covid-19 infection is associated with ventilatory management with elevated positive end-expiratory pressure (PEEP) Mitochondria and microbiota dysfunction in COVID-19 pathogenesis Age-related mitochondrial dysfunction as a key factor in COVID-19 disease Covid-19) sepsis: revisiting mitochondrial dysfunction in pathogenesis, aging, inflammation, and mortality Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia Correlation analysis of the severity and clinical prognosis of 32 cases of patients with COVID-19 Unraveled roles of hyaluronan in severe COVID-19 Association of high SARS-CoV-2 RNAemia with diabetes and mortality in critically ill COVID-19 patients. iScience Systemic innate and adaptive immune responses to SARS-CoV-2 as it relates to other coronaviruses SARS-CoV-2 human T cell epitopes: adaptive immune response against COVID-19 Adaptive immunity to SARS-CoV-2 and COVID-19 Detection of IgG antibody during the follow-up in patients with COVID-19 infection COVID-19 re-infection Clinical characteristics of "re-positive" discharged COVID-19 pneumonia patients in Wuhan Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature Prevalence of asymptomatic SARS-CoV-2 infection : a narrative review Assessment and management of asymptomatic COVID-19 infection: a systematic review Characteristics of asymptomatic COVID-19 infection and progression: a multicenter, retrospective study COVID-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis Severe COVID-19 is marked by a dysregulated myeloid cell compartment Cytokine release syndrome in severe COVID-19. Science Clinical features of patients infected with 2019 novel coronavirus in Wuhan Viral and host factors related to the clinical outcome of COVID-19 Trained immunity carried by non-immune cells Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection Circulating endothelial cells as a marker of endothelial injury in severe COVID -19 Why does chronic inflammation persist: an unexpected role for fibroblasts Multi-organ proteomic landscape of COVID-19 autopsies COVID-19 and pulmonary fibrosis: a potential role for lung epithelial cells and fibroblasts Low molecular weight hyaluronan mediated CD44 dependent induction of IL-6 and chemokines in human dermal fibroblasts potentiates innate immune response Different molecular weight hyaluronic acid effects on human macrophage interleukin 1beta production Intermediate molecular mass hyaluronan and CD44 receptor interactions enhance neutrophil phagocytosis and IL-8 production via p38-and ERK1/2-MAPK signalling pathways Adhesive and/or signaling functions of CD44 isoforms in human dendritic cells A deep learning-based quantitative computed tomography model for predicting the severity of COVID-19: a retrospective study of 196 patients Coagulation abnormalities and thrombosis in patients with COVID-19 Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China Critical neurological features of COVID-19: role of imaging methods and biosensors for effective diagnosis Proteomic and metabolomic characterization of COVID-19 patient sera Omics-driven systems interrogation of metabolic dysregulation in COVID-19 pathogenesis COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status Comorbidity-associated glutamine deficiency is a predisposition to severe COVID-19 Molecular alterations prompted by SARS-CoV-2 infection: induction of hyaluronan, glycosaminoglycan and mucopolysaccharide metabolism Presence of hyaluronan in lung alveoli in severe Covid-19: an opening for new treatment options? Hyaluronan is abundant in COVID-19 respiratory secretions Hyaluronan affects extravascular water in lungs of unanesthetized rabbits The structure and function of hyaluronan: an overview Pathological findings of COVID-19 associated with acute respiratory distress syndrome Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression Dysregulation of immune response in patients Role of CD44 in activation-induced cell death: CD44-deficient mice exhibit enhanced T cell response to conventional and superantigens The characteristics and predictive role of lymphocyte subsets in COVID-19 patients The American-European consensus conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination The journey of hyaluronan research in the journal of biological chemistry Hyaluronan: a master switch between vascular homeostasis and inflammation COVID-19 generates hyaluronan fragments that directly induce endothelial barrier dysfunction. JCI Insight. 2021:e147472 Hyaluronic acid binding protein 2 is a novel regulator of vascular integrity Ultrastructural evidence for direct renal infection with SARS-CoV-2 Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts Evidence for gastrointestinal infection of SARS-CoV-2 Hyaluronic acid (hyaluronan): a review Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Role of glycine 221 in catalytic activity of hyaluronan-binding protein 2 A comparison of mortality-related risk factors of COVID-19, SARS, and MERS: a systematic review and meta-analysis Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records COVID-19: neonatal-perinatal perspectives Persistent COVID-19 symptoms in a community study of 606,434 people in England Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Attributes and predictors of long COVID Serum hyaluronan and aminoterminal propeptide of type III procollagen: variation with age Serum hyaluronan concentration as a marker of angiopathy in patients with diabetes mellitus Elevated plasma hyaluronan levels in pulmonary hypertension Hyaluronan: towards novel anti-cancer therapeutics Serum hyaluronic acid levels during pregnancy and labor Stimulation of histamine release from human basophils by human platelet factor 4 Cold urticaria as a model of mediator release: platelet factor 4, eosinophil cationic protein and histamine Increased hyaluronan (hyaluronic acid) levels in bronchoalveolar lavage fluid after histamine inhalation Hyaluronan regulation of vascular integrity Investigation into cases of hepatitis of unknown aetiology among young children Hyaluronic acid as a non-invasive biomarker of liver fibrosis Serum hyaluronan--a non-invasive test for diagnosing liver cirrhosis Therapeutic antisense oligonucleotides are coming of age Antisense oligonucleotides: an emerging area in drug discovery and development FDA approves eteplirsen for duchenne muscular dystrophy: the next chapter in the eteplirsen saga Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers Interference of ribosomal frameshifting by antisense peptide nucleic acids suppresses SARS coronavirus replication Nucleic acidbased technologies targeting coronaviruses Role of nanotechnology behind the success of mRNA vaccines for COVID-19 Dexamethasone in hospitalized patients with Covid-19 -preliminary report Effect of dexamethasone on days alive and ventilatorfree in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial Metformin treatment was associated with decreased mortality in COVID-19 patients with diabetes in a retrospective analysis Dermal hyaluronan is rapidly reduced by topical treatment with glucocorticoids Metformin decreases hyaluronan synthesis by vascular smooth muscle cells 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer Advances in H1-antihistamines Corticosteroids in management of anaphylaxis; a systematic review of evidence The pharmacological basis of anti-IgE therapy Delayed severe cytokine storm and immune cell infiltration in SARS-CoV-2-infected aged Chinese rhesus macaques COVID-19 as triggering co-factor for cortical cerebral venous thrombosis? Differential responses to steroid hormones in fibroblasts from the vocal fold, trachea, and esophagus Viral miRNA-mediated activation of hyaluronan production as a drug target against COVID-19 Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations We sincerely thank Wei Li, Kaicheng Zhou, Daoping Ru, Peng Xu, Baolong Zhang, Zhicong Yang, Mengxing Liu, and Wenxuan Li from Fudan University for their valuable comments during manuscript preparation. And we appreciate Yue Yu for her kind support in language editing.